Phase 2
N=146
A Nasal Spray With Glucose Oxidase as a Treatment of Common Cold
Common Cold
Bottom Line
View on ClinicalTrials.gov: NCT01883453 ↗Enrolled (actual)
146
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcome: Primary: Reducing Symptoms of a Common Cold — 53; 53; 55; 54 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Glucose oxidase+5%glucose (Device); Saline+5%glucose (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Umeå University
- Primary completion
- May 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Reducing Symptoms of a Common Cold |
53; 53; 55; 54; 55; 49 | — |
Summary
Healthy persons are invited to participate in the study and are given a home protocol (WURSS21), nasal spray and a sample pin. The included persons are told to make a nasopharyngeal sampling from the nose when they are sure that they have caught a common cold. After the sampling they start to spray and also fill in the records daily. The aim of the study is to investigate whether a nasal spray with glucose oxidase could shorten an episode of common cold.
Eligibility Criteria
Inclusion Criteria
- Healthy adults
Exclusion Criteria
- Ongoing allergy
Data sourced from ClinicalTrials.gov (NCT01883453). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.